Oligodendrogliomas: clinical and genetic correlations.
Oligodendrogliomas, once obscure, are now recognized as a relatively common form of primary brain tumour, and are among the most chemosensitive of all solid human malignancies. New histopathological, molecular, and genetic information has, for the first time, allowed the distinction of several subtypes of human glioma with predictable biological and clinical behaviour. Genetic markers are emerging as useful not only for the diagnosis of oligodendroglioma, but also as specific predictors of both the response to treatment and prolonged survival. This review will focus upon the past year of advances in the area of clinical-molecular genetic predictors of glioma behaviour and highlight the importance of these advances in everyday clinical practice.
Perry
J R
JR
Division of Neurology, Department of Medicine, University of Toronto, Sunnybrook and Women's College Health Science Centre, Room A-442, 2075 Bayview Avenue, Toronto, Ontario, Canada M4N 3M5. james.perry@swchsc.on.ca
D000970:Antineoplastic Agents / Q000627:therapeutic use; D001921:Brain / Q000473:pathology; D001932:Brain Neoplasms / Q000175:diagnosis / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology; D018572:Disease-Free Survival; D005819:Genetic Markers / Q000235:genetics; D006801:Humans; D009837:Oligodendroglioma / Q000175:diagnosis / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology
D000970:Antineoplastic Agents; D005819:Genetic Markers